These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32027457)

  • 21. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
    Nwokolo N; Post E; Mageau AS; Shah R; Magee M; Mannino F; Ackerman P; Clark A; Moore K
    HIV Med; 2023 May; 24(5):580-587. PubMed ID: 36372442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
    Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
    O'Mara E; Kasserra C; Huddlestone JR; Wan Y; Soni P; Caceres M; Medlock M; Morrison R; Devinsky O
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2448-54. PubMed ID: 20350942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.
    Parkinson J; Dota C; Källgren C; Gottfridsson C; Bjursell M; Perl S; Kӧrnicke T; Rekić D; Johansson S
    Br J Clin Pharmacol; 2023 Jun; 89(6):1747-1755. PubMed ID: 36504291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
    Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
    J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
    Stier B; Fossler M; Liu F; Caltabiano S
    Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
    Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
    Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model-Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug-Resistant HIV-1 and Relative Bioavailability Assessment in Healthy Adults.
    Thakkar N; Magee M; Goyal N; Abberbock J; Jones C; Taylor J; Chabria S; Moore K
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):991-1000. PubMed ID: 37329260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.
    Hiryak K; Koren DE
    Ann Pharmacother; 2021 Jun; 55(6):792-797. PubMed ID: 32964736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
    Landry I; Zhu L; Abu Tarif M; Hruska M; Sadler BM; Pitsiu M; Joshi S; Hanna GJ; Lataillade M; Boulton DW; Bertz RJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2782-9. PubMed ID: 26902761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
    Gorycki P; Magee M; Ackerman P; Miao X; Moore K
    Xenobiotica; 2022 Jun; 52(6):541-554. PubMed ID: 36083110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.